GILD

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Kite Completes Acquisition of Tmunity

Retrieved on: 
Wednesday, February 22, 2023
Research, Pharmaceutical, Oncology, Hospitals, Other Manufacturing, Genetics, Clinical Trials, Science, Engineering, Biotechnology, Health, Other Science, Manufacturing, Penn, Invention, Therapy, University, CAR, Acquisition, DRS, GILD, Pharmaceutical industry, Chewing

Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

Key Points: 
  • Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
  • The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a strategic research and licensing agreement with the University of Pennsylvania (Penn).
  • In addition, as part of the acquisition, the Tmunity founders, who remain in their roles at Penn, will also provide consulting services to Kite as senior scientific advisors.
  • Penn received sponsored research funding from Tmunity, and now will receive sponsored research funding from Kite following today’s close.

Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), Annual report, LILRB2, PD-1, U.S. Securities and Exchange Commission, ILT4, SELECT, Cancer, GLOBE, IND, Program, Macrophage, Immune system, Gilead Sciences, ICOS, NASDAQ, Private Securities Litigation Reform Act, TITR, Therapy, Patient, CCR8, Tumor microenvironment, GILD, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

Under the terms of the September 2020 agreement, Gilead invested $35.0 million in Jounces common stock and made an $85.0 million upfront payment to Jounce.

Key Points: 
  • Under the terms of the September 2020 agreement, Gilead invested $35.0 million in Jounces common stock and made an $85.0 million upfront payment to Jounce.
  • Jounce led the development of JTX-1811 through IND clearance, after which Gilead obtained the sole right to develop and commercialize the program.
  • Any milestone or royalty paid to Jounce is subject to certain reductions as described in the license agreement.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

Retrieved on: 
Monday, October 17, 2022
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Protein engineering, Therapy, CRS, SEC, Medicine, Risk, Acute myeloid leukemia, AML, DART, CD3, Cytokine release syndrome, NASDAQ, Microdeletion syndrome, MDS, Biotechnology, Patient, Lymphatic system, Research, Twitter, Security (finance), Program, Bispecific monoclonal antibody, Multimedia, Investment, Partnership, Gilead Sciences, Senior, Cancer, Private Securities Litigation Reform Act, HIV, EPS, CD123, Exercise, MD, Doctor of Philosophy, Industry, Science, Blood, Lists of disasters, Toxicity, CEO, Macrogen, GILD, IPR, COVID-19, Half-life, Pharmaceutical industry

Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics DART platform, and two additional bispecific research programs.

Key Points: 
  • Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics DART platform, and two additional bispecific research programs.
  • View the full release here: https://www.businesswire.com/news/home/20221016005052/en/
    A leader in the bispecific antibody space, MacroGenics has extensive experience applying its proprietary DART platform to develop novel therapeutics.
  • MacroGenics bispecific expertise naturally complements Gileads portfolio strengths in immuno-oncology and our growing hematology franchise, said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences.
  • Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference

Retrieved on: 
Tuesday, September 13, 2022
Infectious Diseases, Advocacy Group Opinion, Congressional News, Views, Public Policy, Government, Healthcare Reform, Philanthropy, AIDS, Pharmaceutical, Health, Foundation, HIV/AIDS, HRSA, Park, Safety, FDA, Tenofovir alafenamide, Lawyer, Joe Biden, HHS, Program, Government, Patient, Facebook, Intercontinental, Trump, HIV/AIDS denialism, AHF, Gilead Sciences, Conference, AIDS Healthcare Foundation, AIDS, Congress, Multimedia, Health, GILD, Pharmaceutical industry

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    Gilead officials will be presenting at the conference and the advocates will protest GileadGreediadover the drug companys latest, and illegal move to undermine safety net providers access to 340B program benefits.
  • AIDS Drug Pricing PROTEST targeting Gilead Sciences, Inc.
    111 E. 48th Street (between Park & Lexington Aves.
  • ), New York, NY 10017
    In March of this year, Gilead became the 15th drug manufacturer to place unlawful restrictions on 340B contract pharmacy programs.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth , follow us @aidshealthcare or subscribe to our AHF podcast AHFter Hours.

AHF Protests Gilead over Drug Pricing @ Morgan Stanley Conference

Retrieved on: 
Tuesday, September 13, 2022
Advocacy Group Opinion, Congressional News, Views, Public Policy, Government, Healthcare Reform, Philanthropy, AIDS, Health, Pharmaceutical, Foundation, HIV/AIDS, HRSA, Safety, FDA, Tenofovir alafenamide, Lawyer, Joe Biden, HHS, Program, Government, Patient, Facebook, Trump, HIV/AIDS denialism, Morgan Stanley, AHF, Gilead Sciences, Conference, AIDS, AIDS Healthcare Foundation, Congress, Multimedia, Health, GILD, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220912005989/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220912005989/en/
    AHF has been targeting Gilead Sciences, Inc. as "Greediad" over the drug company's AIDS drug pricing and policies as well as illegal restrictions Gilead is placing on access to its lifesaving drugs through the 340B program.
  • Gilead officials will be presenting at the conference and the advocates will protest Gilead as Greediad over the drug companys latest, and illegal move to undermine safety net providers access to 340B program benefits.
  • AIDS Drug Pricing PROTEST targeting Gilead Sciences, Inc.
  • In March of this year, Gilead became the 15th drug manufacturer to place unlawful restrictions on 340B contract pharmacy programs.

Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors

Retrieved on: 
Monday, May 16, 2022
Oncology, Data Management, Health, Technology, Software, Pharmaceutical, Biotechnology, Senior, Market for corporate control, Engineering, UCSF Benioff Children's Hospital, Hospital, Alphabet Inc., PeopleSoft, Multimedia, Patient, Information technology, NASDAQ, Health, Oracle Hyperion, Automation, Therapy, GILD, GOOG, Pepperdine University, Honeywell, University, Gilead Sciences, Nobel Prize, Robin, GOOGL, Retirement, Salesforce, NYSE, Association of Corporate Treasurers, Board, Technology, Mastercard, Solution, Business administration, LinkedIn, Protein, Twitter, Computer, Drug discovery, CRM, Mastercard Foundation, Tandem Computers, CEO, Pharmaceutical industry, Management, Eikon

View the full release here: https://www.businesswire.com/news/home/20220516005352/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220516005352/en/
    Robin L. Washington has been elected to the Eikon Therapeutics Board of Directors.
  • (Photo: Business Wire)
    Robin Washington is an exceptionally skilled independent board member, said Roger M. Perlmutter, CEO and Chairman of Eikon Therapeutics.
  • There are very few pharmaceutical executives who have been able to manage the sort of extraordinary growth that Robin supervised while at Gilead.
  • Eikon is based in Hayward, California and can be found online via our website or on Twitter or LinkedIn .

Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere

Retrieved on: 
Monday, March 28, 2022
Pharmaceutical, Other Consumer, General Health, Philanthropy, Women, Infectious Diseases, Hospitals, Children, Men, Family, Biotechnology, Other Philanthropy, AIDS, Consumer, Health, Organization, Gaps, City, Nepal Youth Foundation, Research, Program, Gilead Sciences, Cancer, Medicine, Health, Senior, HIV/AIDS denialism, Science, Knowledge, Twitter, Digital, Ageing, COVID-19, Hardship, Public affairs, Solution, HIV, Stigma, Awareness, Education, Health literacy, Outreach, GILD, Pharmaceutical industry

Zeroing In programs aim to increase access to HIV care and services and build on Gileads efforts to help end the epidemic for everyone, everywhere.

Key Points: 
  • Zeroing In programs aim to increase access to HIV care and services and build on Gileads efforts to help end the epidemic for everyone, everywhere.
  • This includes projects from local organizations collaborating to end the HIV epidemic in their respective cities, states, countries or regions.
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. All other trademarks are the property of their respective owners.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks

Retrieved on: 
Wednesday, December 8, 2021
Merck, Oncolytics Biotech, Merck Group, Tafasitamab, Lung cancer, News, Self-signed certificate, Breast cancer, Therapy, CEO, TSX, National Institute, Eli Lilly and Company, 2021 Essex County Council election, Hematology, Lenalidomide, Oncology, Epacadostat, IRENE, Pfizer, NICE, Gilead Sciences, Cancer Drugs Fund, Lymphoma, Ponatinib, Patient, National Institute for Health and Care Excellence, NYSE, GILD, Immunotherapy, Phase, CDF, ONC, Cancer, Pelareorep, Principal investigator, TACSTD2, Neoplasm, Sacituzumab govitecan, ASH, Bristol Myers Squibb, Congress, Principal, TNBC, LLY, Safety, Internal medicine, Science, CAGR, MD, RET, Clinical trial, Survival, NASDAQ, Doctor of Philosophy, NSCLC, Pharmaceutical industry

Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis .

Key Points: 
  • Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis .
  • "These milestones include the reporting of new clinical biomarker data from our AWARE-1 breast cancer study, which we are pleased to be announcing today.
  • It also indicates that changes in peripheral blood T cell populations may be predictive of patient response.
  • We look forward to working with her team in our advanced breast cancer clinical trial to accelerate patient recruitment."